New research has uncovered a surprise link between a common bacterial toxin found in the gut and inflammatory bowel disease (IBD).
The researchers at the John Innes Centre Norwich, UK, working alongside a team of scientists from Brigham and Women’s Hospital (Boston, USA), have helped establish a connection between microcin B17, a well-known toxin produced by E. coli bacteria, and IBD.
IBD includes long-term conditions such Crohn’s disease and ulcerative colitis which together affect more than 300,000 people in the UK.
The research, published today in the peer-reviewed journal Cell, raises prospects of future therapy for IBD sufferers.
The John Innes Centre scientists, led by Professor Tony Maxwell, have been working with microcin B17 for several years in their search for new antibiotics. It is produced by E. coli (Escherichia coli) as a weapon against other bacteria in the gut.
Profesoor Maxwell says: ‘This is largely a chance finding. We have been studying this toxin for its antibacterial properties and we were contacted by Professor Richard Blumberg who leads the Boston group for quite different reasons – they thought there might be a connection between the toxin and IBD.”
The two teams worked together to show that breakdown products from the toxin seem to trigger gut inflammation that is characteristic of IBD.
The research, furthermore, identifies the oxazole class of aromatic organic compounds as a new source of environmental and microbial triggers of gastrointestinal inflammation.
Dr Fred Collin, a postdoctoral researcher in Professor Maxwell’s lab, who carried out key aspects of the work says: ‘These findings will advance our understanding of how gut inflammation associated with IBD may be triggered and offer new hope of potential future therapy.”
The research team point out that advances in genome-wide association studies have established genetic links with the development of IBD. But environmental elements and host reactions have yet to bet precisely defined.
In addition to increasing public understanding of IBD, the study sheds new light on the microbiome, the trillions of bacteria in the gut.
“The bacteria that live inside us have a lot of impact on well-being and the twist here is that it’s not the E. coli bacteria but the toxin that’s produced by the bacteria that appears to have an effect” explains Prof Maxwell.
“They produce these toxins to kill their neighbours in their fight for ecological niches but it appears that the breakdown products of the toxin can initiate gut inflammation.”
See the full findings in the paper ‘Dietary and Microbial Oxazoles Induce Intestinal Inflammation by Modulating Epithelial Derived Aryl Hydrocarbon Receptor Responses‘.